SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

CAPR is drawing attention ahead of the FDAs November 22 decision on Deramiocel for Duchenne muscular dystrophy, after management reaffirmed confidence in the therapy and said its application is in final review. Traders read the CEOs comments on labeling as potentially encouraging and speculate about short covering, while others stress that approval is uncertain given prior FDA concerns.

Figure Technology Solutions, Inc. is a blockchain-native capital marketplace, which engages in connecting origination, funding, and secondary market activity. It operates through the following segments: FTI, Markets, and Other. The FTI segment offers Figure Connect which generates ecosystem and technology fees, and originates, sells, and securitizes home equity line of credit (HELOC) loans that it services. The Markets segment utilizes blockchain technology to develop an exchange for digital assets and credit, with new product offerings including providing interest-bearing stable coin deposits. The company was founded by Michael Scott Cagney and June Ou in 2018 and is headquartered in Reno, NV.

Figure Technology Solutions Inc. - Ordinary Shares - Class A

Figure Technology Solutions Inc

FIGRs steep, volatile selloff is driving a bearish debate, with traders blaming short pressure and insider or pre-IPO shareholder selling while bulls argue the companys growth in HELOC lending and tokenization remains intact. Upcoming earnings are a key focus, with some traders expecting strong operating results to counter concerns about valuation, share overhang, and management.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

RUM is drawing attention after strong Q3 results and its first positive adjusted EBITDA, with traders pointing to Quake AI and the Northern Data GPU business as evidence its AI-infrastructure pivot is gaining traction. Bulls are touting short-squeeze potential, while skeptics question cash needs, ongoing GAAP losses, and the timing of the Georgia data-center expansion.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves stronger-than-expected quarterly results and raised outlook, alongside its large backlog and customer prepayments, eased some concerns about funding its AI infrastructure expansion; the CEOs canceled stock-sale plan also drew bullish notice. Traders celebrated the sharp rebound and speculated about a short squeeze, while skeptics continued to flag debt, interest costs, heavy spending, and potential dilution.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake is drawing attention around its FDA application for sonelokimab in hidradenitis suppurativa, with traders focused on the pending decision on whether the BLA will be accepted and what review timeline it may receive. Bulls point to the drugs clinical results and competitive positioning, while skeptics stress regulatory uncertainty and the costs and dilution risks of launching independently.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius quarterly results are driving attention: revenue growth, improved margins and raised guidance drew praise, while an EPS miss and negative adjusted EBITDA weighed on the shares. Traders are debating the selloff despite the stronger outlook, with some attributing it to short-term trading pressure, though that explanation is speculative.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias generic-drug patent litigation remains unresolved after further deadline extensions, keeping traders focused on when a settlement or court progress might arrive. Frustration over managements limited communication and speculation about a buyout persist, while the latest earnings and raised guidance drew some positive reactions but have not eased concerns about the share price.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Shares are drawing attention after Revolution Medicines reported a strong initial RASONQUE launch, but the stock fell despite the upbeat results. Traders are debating whether the launch can sustain its momentum amid high spending and valuation concerns, while some view the pullback as an overreaction.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins selloff and weakness around key support are weighing on Strategy as a leveraged Bitcoin proxy, with bearish traders warning about dilution, funding pressure and possible forced sales while some investors continue buying dips. Speculation about a potential MSCI index removal adds to concerns, but the community is divided on whether the decline will deepen or reverse.

The Clorox Co. engages in the manufacture and marketing of consumer and professional products. It operates through the following business segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment consists of cleaning products, professional products and vitamins, minerals and supplements mainly marketed and sold in the United States. The Household segments consists of bags and wraps, grilling products and cat litter marketed and sold in the United States. The Lifestyle segment refers to food, natural personal care products and water-filtration products marketed and sold in the United States. The International segment covers products sold outside the United States, excluding natural personal care products. The company was founded by Edward Hughes, Charles Husband, William Hussey, Rufus Myers, and Archibald Taft on May 3, 1913 and is headquartered in Oakland, CA.

Clorox Co.

Clorox is drawing attention after reporting quarterly results that beat estimates while maintaining its fiscal-year sales and adjusted-EPS outlook. Traders largely welcomed the report, though some remain cautious about the companys turnaround and outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TRIB, QTRX, RCON: Why These Stocks Are Surging After-Hours Today 

Equity

The small-cap stocks surged between 6% and 27% after hours on Tuesday. 


Indaptus Therapeutics, Uipath, Trinity Biotech, Sable Offshore And McDonald's: Why These 5 Stocks Are On Investors' Radars Today

INDP, PATH, TRIB, SOC, MCD were among the stocks seen among investors on Tuesday, Dec. 23, 2025.read more...

Novo Nordisk, Trinity Biotech, Starfighters Space, VisionWave, ServiceNow: Stocks Making The Biggest Moves Today

Novo Nordisk shares were up more than 9% in Tuesday’s midday session after the company said that the U.S. FDA has approved its Wegovy pill for weight loss.

Why Did Trinity Biotech Stock Surge Nearly 50% In Premarket Today?

The company secured an order for 9 million units of its TrinScreen HIV rapid diagnostic test.

Trinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data

TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.

Trinity Biotech Stock Marks Best Day Ever On New York Greenlight For Pregnancy Risk Test; Retail Sees More Upside

Trading volume in Trinity Biotech spiked to more than 1,160 times its daily average after regulators cleared the PreClara Ratio test, which helps doctors identify pregnant patients at risk of developing severe preeclampsia.

TRIB, SLXN, STSS: Why Retail Chatter On 3 Nano-Cap Healthcare Stocks Exploded Over 6000%

“Compelling” results from a study, promising pre-clinical data and a public offering got Stocktwits investors buzzing on Tuesday.


Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. It operates through the Americas and Rest of World-Ireland geographical segments. The company was founded by Ronan O'Caoimh and Denis R. Burger in June 1992 and is headquartered in Bray, Ireland.

Trinity Biotech Plc - ADR

Bearish Sentiment

<ul class="summary-bullets"><li>Trinity shares climbed after the company launched Trinovium, a subsidiary focused on liquid-cooling solutions for AI data centers.</li><li>Quanterix gained after new CFO Jason Faessler officially took office, completing a broader leadership overhaul.&nbsp;</li><li>Recon posted the biggest after-hours gain after rebounding from a record low of $0.43.&nbsp;</li></ul>Trinity Biotech (TRIB), Recon Technology (RCON), and Quanterix Corp. (QTRX) each recorded double-digit advances&nbsp;in after-hours trading Tuesday as&nbsp;new growth opportunities, management changes, or technical trading setups stoked investors’ interest.&nbsp;&nbsp;<h2 class="st-heading-2">TRIB Enters AI Data Center Cooling Market With Trinovium Launch&nbsp;</h2>Trinity shares rose after the company launched Trinovium, a new subsidiary focused on developing liquid-cooling solutions for AI data centers. The move comes as data center operators turn to liquid cooling to handle the heat produced by advanced chips and AI systems.&nbsp;The initiative will utilize Trinity’s established manufacturing network in the U.S. and Europe, along with its experience producing high-purity fluids for healthcare applications.Rather than building entirely new production facilities, Trinity plans to repurpose part of its current manufacturing capacity. The company said its facilities already produce large volumes of specialized fluids annually, allowing it to enter the market without substantial additional capital investment and to improve returns from existing operations.Trinovium's first offering is a direct-to-chip cooling fluid designed to support equipment protection, fluid stability, and high levels of purity.&nbsp;<a href="https://stocktwits.com/symbol/TRIB">Trinity Biotech stock</a> traded over 16% higher overnight. On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day.&nbsp;<h2 class="st-heading-2">QTRX Completes Leadership Transition</h2>Quanterix rose after the company’s newly appointed CFO, Jason Faessler, officially assumed the role on Tuesday. The transition follows broader leadership changes, including the appointment of Geoff Albrecht to oversee the diagnostics segment.Investors saw the leadership changes as a way to bring more stability to the company as it continues developing blood tests for neurological diseases, including Alzheimer's.&nbsp;Despite advances in its Alzheimer's testing programs and merger-related cost savings, Quanterix stock has struggled to regain traction, losing roughly half its value in the last 12 months.<a href="https://stocktwits.com/symbol/QTRX">Quanterix stock</a> traded nearly 6% higher overnight. Retail sentiment around the stock remained in ‘neutral’ territory.&nbsp;&nbsp;<h2 class="st-heading-2">RCON Benefits From Technical Rebound</h2>Recon Technology delivered the strongest gain of the group after falling sharply during the regular trading session. The stock hit a record low of $0.43 earlier in the day before buyers returned in after-hours trading.The stock's rebound appears to be driven by speculative buying and investors closing short positions.&nbsp;Recon has seen its shares plunge 83% in the last 12 months. One of the biggest pressures on the stock has been the company’s capital-raising activity. Earlier this year, Recon filed a large mixed-shelf registration that raised expectations for future stock issuance. Those concerns intensified after the company completed an $18 million private placement transaction in April.<a href="https://stocktwits.com/symbol/RCON">Recon Technology stock</a> traded over 27% higher overnight. Retail sentiment around the stock remained in ‘bearish’ territory.&nbsp;So far this year, QTRX and TRIB stocks declined 49% and 55%, respectively, while RCON stock plunged 72%. Year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cdw-stock-jumps-nearly-6-percent-morgan-stanley-bullish-it-play/cZKwB8FR7as">CDW Stock Jumps Nearly 6% — Why Morgan Stanley Is Growing More Optimistic On This IT Play</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Exterior shows Quanterix offices in Lexington.

Trinity Biotech (TRIB), Recon Technology (RCON), and Quanterix Corp. (QTRX) each recorded double-digit advances&nbsp;in after-hours trading Tuesday as&nbsp;new growth opportunities, management changes, or technical trading setups stoked investors’ interes

Quanterix Corp

Recon Technology Ltd - Ordinary Shares - Class A

Trinity Biotech plc

Yes, by year-end

Yes, but not this year

No, he stays as CEO

He steps down on his own

Do you think Jensen Huang will be removed as Nvidia’s ($NVDA) CEO?

Stocktwits

Do you think Jensen Huang will be removed as Nvidia’s (

Stocktwits Polls

$TRIB Microfloat (600K shares) needs to reach and sustain the price of $22 to sustain listin NASDAQ requirements. That is a 175% upside from the current price. The first gap has been filled. Ultra risky play 🔥🪖🫡☝️

Resistance Breakers

$TRIB Perceptive converted the maximum at the new, lower price very quickly.  That’s a data point.

Deepthinker

$TRIB another $4M from Perceptive but with better dilution for Perceptive.  Suggests CGM or Trinovium deal is still away off.

eugene mcdonnell

$TRIB The Nasdaq decision should be made by approx Nov 18 based on typical timescales. They have to announce it. Decision will be very informative...obviously.

$TRIB In the event there is no partner ready to take a substantial stake, the obvious play would be to spin-out the CGM as a separate company, and then sell part of it.  The same would go for the AI cooling business, assuming there is a marketable product there.  This works for Perceptive, which cuts its debt exposure and provides it with stakes in three potentially valuable companies.

$TRIB Biosensor startup SAVA Tech just raised $36 million (Ascencia partial acquisition).  Don’t know the valuation.  $150 million at least.

$TRIB Sleep tight, next time check the mirror before picking up a random fight. You really shouldn't have defied a decorated warrior's might, now your head will hang on my wall for everyone's sight. Sweet 🫶
🔥🪖🫡☝️

Feed

News

Sentiment

Fundamentals

Info

TRIB Trinity Biotech plc

Fundamentals

Latest TRIB News